Key Highlights
- Antony Loebel, M.D., appointed as Chief Medical Officer and President of Clinical Development.
- Lana Gladstein, J.D., joins as General Counsel.
- Strengthened executive team aims to advance Seaport’s novel neuropsychiatric medicines.
Source: Business Wire
Notable Quotes
- “I’m delighted to welcome two more outstanding members to our senior executive team. As we design and run studies to advance our clinical-stage pipeline of novel therapeutics focused on important mental health conditions, Tony’s deep understanding of neuropsychiatric drug development builds on our team’s distinct advantages. We are rapidly growing our company and Lana’s experience across all facets of legal, including corporate governance, transactions, and IP, will be an important resource to Seaport. I’m thrilled to have both Tony and Lana onboard.” — Daphne Zohar, Founder and Chief Executive Officer at Seaport
- “I’m excited to join Daphne, Steve and the rest of the incredible team at Seaport to help further advance its robust pipeline of important neuropsychiatric medicines. We have a unique opportunity to make a meaningful difference for the millions of people struggling with serious mental health conditions, including depression and anxiety.” — Dr. Antony Loebel, Chief Medical Officer and President of Clinical Development at Seaport Therapeutics
- “I am humbled and thrilled to be joining the team at Seaport. This is a team with an incredible track record of achievement and an unwavering commitment to advancing innovative therapeutics for patients. I look forward to leveraging my experience to build upon Seaport’s strong legal foundation and support its continued growth.” — Lana Gladstein, General Counsel at Seaport Therapeutics
SoHC's Take
The strategic appointments of Antony Loebel, M.D., and Lana Gladstein, J.D., to Seaport Therapeutics’ executive team underscore the company’s commitment to advancing its pipeline of innovative neuropsychiatric medicines. Dr. Loebel’s extensive experience in CNS drug development, particularly his successful tenure at Sunovion Pharmaceuticals, brings invaluable expertise to Seaport’s clinical development efforts. Meanwhile, Ms. Gladstein’s comprehensive legal background will be instrumental in navigating the complexities of corporate governance and intellectual property as Seaport continues its rapid growth. These appointments are poised to strengthen Seaport’s leadership and accelerate the development of its promising therapeutics, ultimately aiming to address critical unmet needs in mental health.
